Ibrutinib monotherapy shows ten-year durable efficacy across CLL subtypes
read at onclive ↗Positive readoutPositive
Ibrutinib monotherapy has demonstrated lasting effectiveness in chronic lymphocytic leukemia across multiple disease subtypes.
Data reveal that patients, including those with TP53 mutations, maintain disease control for up to ten years while on the therapy.
These long-term results highlight the drug’s potential to provide sustained benefit for a broad CLL population.
source
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Ibrutinib Monotherapy Yields Decade-Long Durable Efficacy in Across CLL Subtypes”
read at onclive ↗
comments(0)
5-min edit window · permanent after that